Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Hideki Uryu, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 5515.

https://doi.org/10.1182/blood-2019-122977

Published: 2019

Journal Articles

Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing

Blood (2015) 126 (23): 709.

https://doi.org/10.1182/blood.V126.23.709.709

Published: 2015

Journal Articles

Application Of The Revised International Prognostic Scoring System In Korean Patients With MDS and Clinical Significance Of Clonal Evolution

Jae Hyeon Park, MD, Si Nae Park, Jiseok Kwon, Kyongok Im, Jung Ah Kim, MD, Qute Choi, MD, Seon Young Kim, MD, Sang Mee Hwang, MD, Inho Kim, Sung-Soo Yoon, Seonyang Park, MD, PhD, Dong Soon Lee, MD, PhD

Blood (2013) 122 (21): 5217.

https://doi.org/10.1182/blood.V122.21.5217.5217

Published: 2013

Journal Articles

Clinical Factors Predictive Of Myelofibrotic Evolutions In Patients With Essential Thrombocythemia and Polycythemia Vera

Mario Tiribelli, MD, Federico De Marchi, MD, Daniela Barraco, MD, Luciana Marin, MD, Erika Codarin, PhD, Silvia Buttignol, MD, Daniela Damiani, MD, Renato Fanin, MD

Blood (2013) 122 (21): 4082.

https://doi.org/10.1182/blood.V122.21.4082.4082

Published: 2013

Journal Articles

New Method for in Vivo Hematopoiesis Microenvironment Research: Tissue-Engineering-Bone Femur Repairing Model and Semi-Solid Decalcification

Shan Jiang, MD&PhD, Qianli Jiang, MD&PhD, Liqiong Zhu, Feili Chen, M.D., Lezhong Yuan, Peiran Zhao, Mo Yang, M.D.Ph.D, Jing Sun, Fanyi Meng, MD

Blood (2012) 120 (21): 4732.

https://doi.org/10.1182/blood.V120.21.4732.4732

Published: 2012

Journal Articles

A Monocentric, Prospective, Observational Study On Vaso-Occlusive Crisis (VOC) in Adult Sickle-Cell Disease (SCD).

Pablo Bartolucci, MD, PhD, Anoosha Habibi, Mehdi Khellaf, Anne sophie Lascaux, Aline Santin, Françoise Roudot Thoraval, Stéphane Moutereau, Hélène Jouault, Yves Levy, MD, PhD, Bertrand Renaud, Frederic Galacteros, MD PhD, Bertrand Godeau, MD

Blood (2012) 120 (21): 2115.

https://doi.org/10.1182/blood.V120.21.2115.2115

Published: 2012

Journal Articles

Genetic Basis of Myeloid Proliferation Related to Down Syndrome

Blood (2012) 120 (21): 535.

https://doi.org/10.1182/blood.V120.21.535.535

Published: 2012

Journal Articles

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Shaji Kumar, Ian Flinn, Paul G. Richardson, Parameswaran Hari, Natalie Callander, Stephen J. Noga, A. Keith Stewart, Francesco Turturro, Robert Rifkin, Jeffrey Wolf, Jose Estevam, George Mulligan, Hongliang Shi, Iain J. Webb, S. Vincent Rajkumar

Blood (2012) 119 (19): 4375–4382.

https://doi.org/10.1182/blood-2011-11-395749

Published: 2012

Journal Articles

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

Shaji Kumar, MD, Ian W. Flinn, MD, PhD, Paul G Richardson, MD, Parameswaran Hari, MD, Natalie Scott Callander, MD, Stephen J. Noga, MD, PhD, A. Keith Stewart, MD, Jonathan Glass, MD, FACP, Robert M. Rifkin, MD, Jeffrey L Wolf, MD, Jose Estevam, BS, George Mulligan, PhD, Hongliang Shi, MS, Iain J. Webb, MD, FRCPC, S. Vincent Rajkumar, MD

Blood (2010) 116 (21): 621.

https://doi.org/10.1182/blood.V116.21.621.621

Published: 2010

Journal Articles

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

Shaji Kumar, Ian W. Flinn, Parameswaran N. Hari, Natalie Callander, Stephen J. Noga, A. Keith Stewart, Jonathan Glass, Noopur Raje, Robert M. Rifkin, Hongliang Shi, Iain J. Webb, Paul G. Richardson, S. Vincent Rajkumar

Blood (2009) 114 (22): 127.

https://doi.org/10.1182/blood.V114.22.127.127

Published: 2009

Journal Articles

Validation of Updated Cytogenetic Risk Classification in Patients with Myelodysplastic Syndrome: Retrospective Study at Single Institution.

Jina Yun, Jee Hyun Kong, Jung A. Kim, Dong Hwan Dennis Kim, Jun Ho Jang, Kihyun Kim, Chul Won Jung

Blood (2009) 114 (22): 4837.

https://doi.org/10.1182/blood.V114.22.4837.4837

Published: 2009

Journal Articles

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Shaji Kumar, MD, Ian W Flinn, MD, PhD, Stephen J. Noga, MD, PhD, Parameswaran Hari, MD, MS, Robert M. Rifkin, MD, Natalie Scott Callander, MD, Manish Bhandari, MD, Jeffrey Lee Wolf, MD, Cristina Gasparetto, MD, Amrita Krishnan, MD, FACP, Daren D Grosman, MD, PhD, Jonathan Glass, MD, Entezam Asim Sahovic, MD, Hongliang Shi, MS, Iain J. Webb, MD, Paul Richardson, MD, S. Vincent Rajkumar, MD

Blood (2008) 112 (11): 93.

https://doi.org/10.1182/blood.V112.11.93.93

Published: 2008

Journal Articles

Genetic Reconstruction of Follicular Lymphoma Evolutions: Sμ Mutations Studies Suggest Two Progression Patterns, Early Direct or Late from FL “Stem Cells”.

Philippe Ruminy, PhD, Fabrice Jardin, MD, PhD, Françoise Parmentier, Nathalie Contentin, MD, Gérard Buchonnet, MD, PhD, Herve Tilly, MD, Christian Bastard, MD, PhD

Blood (2007) 110 (11): 182.

https://doi.org/10.1182/blood.V110.11.182.182

Published: 2007

Journal Articles

Paroxysmal Nocturnal Hemoglobinuria (PNH): Long-Term Epidemiological Study.

Regis Peffault de Latour, MD, Jean Y. Mary, PhD, Celia Salanoubat, MD, Louis Terriou, MD, Gabriel Etienne, MD, Mohamad Mohty, MD, PhD, Sophie Roth, MD, Sophie de Guibert, MD, Jean Y. Cahn, MD, Gerard Socie, MD, PhD

Blood (2006) 108 (11): 973.

https://doi.org/10.1182/blood.V108.11.973.973

Published: 2006

NARROW

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing

Application Of The Revised International Prognostic Scoring System In Korean Patients With MDS and Clinical Significance Of Clonal Evolution

Clinical Factors Predictive Of Myelofibrotic Evolutions In Patients With Essential Thrombocythemia and Polycythemia Vera

New Method for in Vivo Hematopoiesis Microenvironment Research: Tissue-Engineering-Bone Femur Repairing Model and Semi-Solid Decalcification

A Monocentric, Prospective, Observational Study On Vaso-Occlusive Crisis (VOC) in Adult Sickle-Cell Disease (SCD).

Genetic Basis of Myeloid Proliferation Related to Down Syndrome

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

Validation of Updated Cytogenetic Risk Classification in Patients with Myelodysplastic Syndrome: Retrospective Study at Single Institution.

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Genetic Reconstruction of Follicular Lymphoma Evolutions: Sμ Mutations Studies Suggest Two Progression Patterns, Early Direct or Late from FL “Stem Cells”.

Paroxysmal Nocturnal Hemoglobinuria (PNH): Long-Term Epidemiological Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only